Helen Tremlett’s Google Scholar Profile
A sample of publications and presentations is presented below.
Published refereed papers
1. Tremlett H, Luscombe DK, Wiles CM: Use of Corticosteroids in Multiple Sclerosis byUK Consultant Neurologists. Journal of Neurology, Neurosurgery and Psychiatry 1998;65:362-365.
2. Tremlett H, Luscombe DK: Multiple Sclerosis. Pharmaceutical Journal 1998;260:29-38.
3. Tremlett H, Wiles CM: Oral or intravenous? The evidence for corticosteroids in Multiple Sclerosis. Progress in Neurology and Psychiatry 1999;3(1):19-23
4. Tremlett H, Luscombe DK: Beta-interferon in the treatment of Multiple Sclerosis. Journal of Applied Therapeutic Research 1999;2(4):235-242.
5. Tremlett H, Wiles CM, Luscombe DK Non-prescription medicine use in an MS clinic population; British Journal of Clinical Pharmacology 2000;50(1):55-60.
6. Tremlett H, Wiles CM, Luscombe DK Prescribing for Multiple Sclerosis patients in General Practice: a case-control study Journal of Clinical Pharmacy and Therapeutics; 2001;26(6):437-444.
7. Tremlett H, J Evans, C Rogers, CM Wiles, DK Luscombe Asthma and Multiple Sclerosis: an inverse association in a case-control general practice population; Quarterly Journal of Medicine; 2002;95:753-756.
8. Tremlett H, Oger J. Interrupted therapy: stopping and switching of the beta-interferons prescribed for MS Neurology 2003;61:551-554.
9. Tremlett H, Oger J Adherence from across the pond: six-years of experience with the beta-interferons prescribed for Multiple Sclerosis, Pharmaceutical Journal 2003; 271:649-653.
10. Tremlett H, Yoshida E, Oger J. Liver injury associated with the IFNBs for MS: a comparison between IFNB-1b(sc), IFNB-1a (sc) and IFNB-1a (im). Neurology 2004;62:628-631.
This publication was selected by Neurology to have an accompanying Patient Page:
Aguilar, M. MS treatment: Some safety issues to keep in mind. Neurology 2004;62:8-9. As stated by the journal, the Neurology Patient Page provides ‘a critical review of ground- breaking discoveries in neurological research that are written especially for patients and their families.’
11. Tremlett H, Oger J. Elevated aminotransferases during treatment with Beta-Interferon for Multiple Sclerosis: actions and outcomes. Multiple Sclerosis 2004;10:298-301
12. Tremlett H, Porciuncula J, Gibbs E, Oger J Binding antibodies and aminotransferases in beta-interferon beta treated patients with multiple sclerosis. Journal of Applied Therapeutic Research 2004;5(1):12-16
13. Tremlett H, Oger J Hepatic injury, liver monitoring and the beta-interferons for Multiple Sclerosis (Review) Journal of Neurology 2004;251:1297-1303
14. Tremlett H, Porciuncula J, Oger J Treatment with beta-interferon prior to glatiramer acetate diminishes the serum IgG response in multiple sclerosis patients. Journal of Applied Therapeutic Research 2004;5(2):12-16.
15. Tremlett H, Paty D, Devonshire V The natural history of primary progressive MS in British Columbia, Canada. Neurology. 2005;65:1919-1923.
16. Tremlett H, Paty D, Devonshire V. Disability progression in MS is slower than previously reported. Neurology. 2006;66:172-177.
This publication was highlighted by Neurology. This is the most frequently read section of the Journal; a limited number of papers are highlighted each issue:
Disability progression in multiple sclerosis (MS) Neurology. 2006;66:157
And had an accompanying Commentary:
Pittock, S. Therapeutic decision making in MS: Impact of a slower disability progression. Neurology. 2006;66:157.
17. Tremlett H,Devonshire V. Does the season or month of birth influence disease progression in multiple sclerosis? Neuroepidemiology 2006;26:195-198
18. Tremlett H,Devonshire V. Is late onset multiple sclerosis associated with a worse outcome? Neurology 2006;67:954-959
19. Tremlett H, Seemüller S, Zhao Y, Yoshida EM, Oger J. Petkau J. Liver test abnormalities in multiple sclerosis: findings from placebo treated patients. Neurology 2006;67:1291-1293
20. Sayao AL, Devonshire V, Tremlett H. Longitudinal Follow-up of Benign MS at 20 years. Neurology. 2007 Feb 13;68(7):496-500.
Contribution: Methodological advice, carried out all statistical analyses, presentation of data graphically and in table form. Guided drafting of manuscript, critical review of final manuscript (20% effort). Corresponding author.
This publication was highlighted by Neurology:
Benign MS at 20 years Neurology. 2007;68:478
And had an accompanying Commentary:
Pittock, S. Does benign multiple sclerosis today imply benign multiple sclerosis tomorrow?
Implications for treatment. Neurology. 2007;68:480-481.
21. Tremlett H, Oger J Ten years of adverse drug reaction reports for the multiple sclerosis immunomodulatory therapies: a Canadian perspective. Multiple Sclerosis 2008; 14:94-105
22. Tremlett H, Zhao Y,Devonshire V. The natural history of secondary-progressive multiple sclerosis Multiple Sclerosis 2008. 14: 314–324
This paper was accompanied by an Editorial: Confavreux, C. Defining the natural history of MS: the need for complete data and rigorous definitions Multiple Sclerosis 2008; 14(3): 289 – 291.
23. Forwell S, Brunham S, Tremlett H, Morrison W, Tentzerakis S, Bogle N, Oger J. Primary and non-primary fatigue in multiple sclerosis. International Journal of MS Care. 2008;10:14-20
Contribution: Assessing the effects of medication on fatigue. I contributed to the study design (collection of drug data) and provided drug information for individual patient cases. I also helped with the statistical analysis and critical review of the final manuscript. 5% effort
24. Koch M, De Keyser J, Tremlett H Timing of birth and disease progression in multiple sclerosis. Multiple Sclerosis 2008; 14:793-798.
Contribution: 50%
25. Tremlett H, Van der Mei I, Pittas F, Blizzard L, Paley G, Dwyer T, Taylor B, Ponsonby AL. Adherence to the immunomodulatory drugs for multiple sclerosis: contrasting factors affect stopping drug and missing doses. Pharmacoepidemiology and Drug Safety 2008 17(6):565-76.
26. Tremlett H, Zhao Y, Joseph J,Devonshire V and the UBC MS Clinic Neurologists. Relapses in multiple sclerosis are age and time-dependent. J Neurol Neurosurg Psychiatry 2008;79;1368-1374
27. Tremlett H, van der Mei I, Pittas F, Blizzard L, Paley G, Mesaros G, Woodbaker R, Nunez M, Dwyer T, Taylor B, Ponsonby AL. Monthly ambient sunlight, infections and relapse rates in multiple sclerosis. Neuroepidemiology. 2008; 31: 271-279
Accompanying Commentary:
Kesselring, J. Sunshine on MS. Neuroepidemiology. 2008; 31: 280-281
28. Tremlett H, Zhao Y, Devonshire V. Natural history comparisons of primary and secondary progressive multiple sclerosis reveals differences and similarities. Journal of Neurology. 2009 Mar;256(3):374-81
29. Tremlett H, Yousefi M, Devonshire V, Rieckmann P, Zhao Y and the UBC Neurologists. The impact of multiple sclerosis relapses on progression diminishes with time. Neurology 2009; 73:1616-1623
Accompanying Editorial:
Editorial: Ruth Ann Marrie and Gary Cutter Relapses in multiple sclerosis. Important or not? Neurology 2009; 73:1612-1613
The paper was selected to appear on-line, ahead of print as a rapid communication with the ‘hare’ logo (only 1-5 papers are selected from each edition of the journal to appear in this form). In addition, the work was selected by Neurology, for the American Academy of Neurology’s press release program.
30.Koch M, Kingwell E, Rieckmann P and Tremlett H and the UBC Neurologists. The natural history of primary progressive MS. Neurology 2009; 73 1996-2002
Contribution of my group: 100%.
31. Kingwell E, Leung A, Roger E, Duquette P, Rieckmann P, Tremlett Hand the UBC MS Neurologists. Factors associated with delay to medical recognition in two Canadian multiple sclerosis cohorts. Journal of the Neurological Sciences 2010; 292:57-62
Contribution of my group: 80%.
32. Kingwell E, Koch M, Leung B, Isserow S, Geddes J, Rieckmann P, Tremlett H, and the UBC MS Clinic Neurologists. Cardiotoxicity and other adverse events associated with mitoxantrone treatment for MS. Neurology 2010; 74 1822-1826
Contribution of my group: 90%.
33. Koch M, Zhao Y, Yee I, Guimond C, Kingwell E, Rieckmann P, Sadovnick S, Tremlett H. Age at disease onset in familial and sporadic primary progressive multiple sclerosis. Multiple Sclerosis. 2010. 2010;16 694-700
Contribution of my group: 80%.
34. Tremlett H, Zhao Y, Rieckmann P, Hutchinson M. New perspectives in the natural history of multiple sclerosis (Review). Neurology 2010;74:2004-2015
35. Simpson S, Taylor B, Blizzard L, Ponsonby AL, Pittas F, Tremlett H, Dwyer T, Gies P & Van der Mei I Higher levels of serum 25-hydroxyvitamin D3 are associated with a reduced risk of relapse in multiple sclerosis. Annals of Neurology 2010;68:193-203
Contribution: 5%.
36. Koch M, Kingwell E, Rieckmann P, Tremlett H, and the UBC MS Clinic Neurologists. The natural history of secondary progressive MS. Journal of Neurology, Neurosurgery and Psychiatry. 2010;81(9):1039-43.
Contribution of my group: 100%.
Accompanying Editorial:
Chataway J. Progression is likely to occur earlier in young men with motor onset symptoms. Journal of Neurology, Neurosurgery and Psychiatry 2010;81:944-5
37. Shirani A, Tremlett H. The effect of smoking on the symptoms and progression of multiple sclerosis: a review.J Inflamm Res, 2010,3:115-26
Contribution of my group: 100%.
38. Chan S, Kingwell E, Oger J, Yoshida E, Tremlett H. High-dose frequency beta-interferons increase the risk of liver test abnormalities in multiple sclerosis: a longitudinal study. Multiple Sclerosis Journal 2011;17 361-367
Contribution of my group: 100%.
39. van der Kop ML, Pearce MS, Dahlgren L, Synnes A, Sadovnick AD, Sayao A, Tremlett H Neonatal and delivery outcomes in women with multiple sclerosis. Annals of Neurology. 2011 Jul;70(1):41-50
Contribution of my group: 100%.
40. Sayao AL, Bueno AM, Devonshire V, and the UBC MS Clinic Neurologists Tremlett H The psychosocial and cognitive impact of longstanding ‘benign’ multiple sclerosis Multiple Sclerosis Journal 2011 Nov;17(11):1375-83
Contribution of my group: 100%.
41. Kingwell E, van der Kop M, Zhao Y, Shirani A, Zhu F, Oger J and Tremlett H. Relative mortality and survival in multiple sclerosis: Findings from British Columbia, Canada. Journal of Neurology, Neurosurgery & Psychiatry 2012 Jan;83(1):61-6. Epub 2011 Aug 23
Contribution of my group: 100%.
42. Shirani A, Zhao Y, Kingwell E, Rieckmann P, Tremlett H Temporal trends of disability progression in multiple sclerosis Multiple Sclerosis Journal 2011 Sep 30. [Epub ahead of print]
Contribution of my group: 100%.
43. Lu E, Dahlgren L, Sadovnick AD, Sayao A, Synnes A, Tremlett H Perinatal outcomes in women with multiple sclerosis exposed to disease-modifying drugs. Multiple Sclerosis Journal 2011 Sep 13. [Epub ahead of print]
Contribution of my group: 100%.
44. Saeedi J, Rieckmann P, Yee I, Tremlett H and the UBC MS clinic neurologists. Characteristics of multiple sclerosis in aboriginals living in British Columbia (BC) Canada. Multiple Sclerosis Journal 2012 Mar 1. [Epub ahead of print]
Contribution of my group: 90%.
45. Evans C, Tam J, Kingwell E, Oger J, the BC MS Neurologists, Tremlett H. Long-term persistence with the immunomodulatory drugs for multiple sclerosis: a retrospective database study. Clinical Therapeutics. 2012 Feb;34(2):341-50
Contribution of my group: 100%.
46. Marrie RA, Yu N, Leung S, Elliott L, Caetano P, Warren S, Wolfson C, Patten S, Svenson L, Tremlett H, Fisk J, Blanchard J,for the CIHR Team in the Epidemiology and Impact of Comorbidity on Multiple Sclerosis. Rising prevalence of vascular comorbidities in MS: validation of administrative definitions for diabetes, hypertension, hyperlipidemia. Multiple Sclerosis Journal. 2012 Feb 10. [Epub ahead of print]
Contribution of my group: 5% [I helped gain funding for the overall study; drafted the original study design and edited the manuscript].
47. Kowalec K, Carleton B, Tremlett H. The potential role of pharmacogenomics in the prevention of serious adverse drug reactions in multiple sclerosis. Multiple Sclerosis and Related Disorders. 2013 Mult Scler Related Dis, 2 (3): 183-192.
Contribution of my group: 100%.
48. Kowalec K, Kingwell E, Yoshida EM, Marrie RA, Kremenchutzky M, Campbell T, Wadelius M, Carleton BC, Tremlett H. (2014) Characteristics associated with drug induced liver injury from interferon beta in multiple sclerosis patients. Expert Opin Drug Saf, 13(10):1305-17.
Contribution of my group: 100%.
49. Tremlett H, Zhu F, Petkau J, Oger J, Zhao Y. Natural, innate improvements in multiple sclerosis disability. Multiple Sclerosis Journal. 2012;18(10):1412-1421. doi:10.1177/1352458512439119
Contribution of my group: 100%.
Accompanying Editorial: TBA
50. Lu E, Wang BW, Guimond C, Synnes A, Sadovnick D, Tremlett H. Disease-modifying drugs for multiple sclerosis in pregnancy: a systematic review. Neurology. 2012;79(11):1130-1135. doi:10.1212/WNL.0b013e3182698c64
51. Makhani, N., Tremlett, H. The multiple sclerosis prodrome. Nat Rev Neurol 17, 515–521 (2021). https://doi.org/10.1038/s41582-021-00519-3
52. Tremlett H and Waubant E. MS Minute: Multiple Sclerosis & the Gut Microbiome. Practical Neurology 2022 (available online 27-July-2022; https://practicalneurology.com/articles/2022-july-aug/ms-minute-multiple-sclerosis-the-gut-microbiome)
53. Marrie RA, Allegretta M, Barcellos LF, Bebo B, Calabresi PA, Correale J, Davis B, De Jager PL, Gasperi C, Greenbaum C, Helme A, Hemmer B, Kanellis P, Kostich W, Landsman D, Lebrun-Frenay C, Makhani N, Munger KL, Okuda DT, Ontaneda D, Postuma RB, Quandt JA, Roman S, Saidha S, Sormani MP, Strum J, Valentine P, Walton C, Zackowski KM, Zhao Y, Tremlett H. From the prodromal stage of multiple sclerosis to disease prevention. Nat Rev Neurol. 2022 Jul 15. doi:10.1038/s41582-022-00686-x. Epub ahead of print. PMID: 35840705.
In Press
Invited Editorials
1. Banwell, B and Tremlett H Coming of Age: The Use of Immunomodulatory Therapy in Paediatric Multiple Sclerosis. Neurology 2005; 64:778-779.
Contribution: Independently reviewed article referred to in the Editorial. Co-wrote the invited editorial. 50% effort.
2. Kingwell, E and Tremlett H. Interferons and Multiple Sclerosis: Is it plausible that beta-interferon treatment could influence the risk of cancer among MS patients? Expert Review of Neurotherapeutics 2009; 9:1263-1265
Contribution: Co-wrote the invited editorial. 50% effort.
3. Franklin, G and Tremlett H. Multiple sclerosis and pregnancy: What should we be telling our patients? Neurology 2009; 73(22):1820-2
Contribution: Co-wrote the invited editorial. 50% effort.
4. Tremlett H. Epidemiology in multiple sclerosis has had its day: there are no more unanswered questions – No.Mult Scler. 2012 Feb;18(2):138-9
5. Tremlett H and Lucas R. The risks for falls and fractures in multiple sclerosis. Neurology (accepted Feb/2012)
Book Chapters
1. Marrie RA, Tremlett H Chapter 5: Epidemiology of multiple sclerosis. In: The Future of MS Treatment. Editors: Cohen J and Rudick R. 2011. Cambridge University Press
Research Letters and case reports
1. Tremlett H: Oral versus intravenous corticosteroids in acute relapses of Multiple Sclerosis. Lancet 1997;340:1696-1697.
2. Tremlett H, Luscombe DK: Unsubstantiated treatment (letter). Pharmaceutical Journal 1998;260:308.
3. Tremlett H, Luscombe DK: Use of desmopressin (letter). Pharmaceutical Journal 1998;260:201.
4. Tremlett H, J Evans, C Rogers, CM Wiles, DK Luscombe General practitioners’ prescribing data for multiple sclerosis patients indicates a link with asthma; British Journal of General Practice; 2000; 50(453);323.
5. Tremlett H. Effects of seasons on MRI-measured disease activity in patients with MS); Ann Neurol; 2001;50(3);422.
6. Tremlett H, Griggs RC. Liver and thyroid function and autoimmunity during interferon-ß1b treatment for MS Neurology; 2002;58:1868.
7. Tremlett H, Yoshida E, Oger J. Liver injury associated with the IFNBs for MS: a comparison between IFNB-1b(sc), IFNB-1a (sc) and IFNB-1a (im) Neurology 2004;63:1142-1143 (http://www.neurology.org/cgi/content/full/63/6/1142?etoc)
8. Tremlett H, Traboulsee T. Randomized multicenter trial of natalizumab in acute MS relapses: clinical and MRI effects. Neurology; 2005;64(1):174.
9. Tremlett H: What went wrong in the natalizumab trials Comment? Lancet 2006; 367:1484-1485
10. Tremlett H, Sayao AL, Devonshire V. Longitudinal follow-up of ‘benign’ multiple sclerosis at 20 years. Neurology 2007;69(9):938
11. Koch M, Mostert J, De Keyser J, Tremlett H, Filippini G. Interferon-beta treatment and the natural history of relapsing-remitting multiple sclerosis. Ann Neurol. 2007; 63(1):125-126
Contribution: Drafting and editing letter. 20% effort
12. Gibbs E, Tremlett H, Ball N, Hashimoto S Malignant melanoma in a multiple sclerosis patient with persistent neutralizing antibodies to interferon beta. European Journal of Neurology 2008, 15(1): e4
Contribution: Drafting and editing letter. 10% effort
13. Hashimoto S, Ball N, Tremlett H Progressive lipoatrophy after cessation of glatiramer acetate injections: a case report. Multiple Sclerosis. 2009;15:521-522
Contribution: Drafting and editing case report. 30% effort
14. Tremlett H, Fu P, Yoshida E, Hashimoto S Symptomatic liver injury (hepatotoxicity) associated with administration of complementary and alternative products (Ayurveda-AP-Mag Capsules®) in a beta-interferon treated multiple sclerosis patient. European Journal of Neurology 2011 Jul;18(7):e78-9
Contribution of my group: 80%.
15. Kowalec K, Yoshida EM, Traboulsee A, Carleton BC, Tremlett H. Suspected autoimmune hepatitis and primary biliary cirrhosis unmasked by interferon-beta in a multiple sclerosis patient. Multiple Sclerosis and Related Disorders 2012 2(1): 57-59.
